Apollo Hospitals Enterprise Ltd Q2 FY2024 Concall Summary

Key Takeaways

• Steady hospital growth, margin investment phase: IP volumes grew 4% and surgical volumes 7% YoY, while ARPOB rose 14% driven by insurance mix and bed-category upgrades. Hospital EBITDA margin dipped ~75 bps to 24.9% as the company invested in 100 new doctors and higher marketing.
• Pharmacy margin recovery on track: Omnichannel front-end grew 21% and offline distribution 17%; pharmacy EBITDA margin improved sequentially from 9.7% in Q4 to 12.2% in Q2, with management targeting another 3–4% improvement in six months.
• Apollo 24/7 approaching breakeven: The digital platform added 0.2 crore users (total 2.9 crore) and remains on track for operational breakeven in Q4 FY24, with quarterly opex run rate expected to fall to ₹150 crore or lower.
• Expansion pipeline fully loaded: Three new hospitals announced (Pune, Kolkata, Rourkela) plus ongoing 2,300-bed addition across eight locations at a cost of ₹3,400 crore over three years, all funded from internal accruals with possible small debt only in year three.
• What to watch next quarter: Whether the 100 new doctors begin converting their guarantees into revenue, the pace of pharmacy margin expansion toward 20%, and any update on HealthCo fundraise valuation.

Hospital Performance & Margins

• Volume mix shift: IP volumes grew 4% YoY but surgical volumes outpaced at 7%, a favorable mix for ARPOB. A delayed monsoon reduced medical admissions in the Southern region while other regions saw significantly higher growth.
• ARPOB surge explained: ARPOB rose 14% YoY, above the historical run rate, driven by three structural shifts: patients opting for higher-category beds as general wards were reconfigured, better realizations from renegotiated insurance contracts over two years old, and prior-quarter price increases continuing to prevail. Insurance penetration has moved from 25–30% pre-COVID to 43% now.
• Case mix improvement: Cardiac, oncology, neuro and orthopedics contributed significant high-margin revenue, supporting ARPOB growth. Management now models ARPOB growth at 7–8% going forward, not the elevated 14% seen this quarter.
• Margin headwinds are investment-led: Healthcare services EBITDA margin fell ~75 bps YoY to 24.9% due to guaranteed money for 100 new doctors added to the pipeline and a 0.5% increase in marketing spend. These doctor costs are one-time; as the new cohort ramps up, margin improvement is expected over time.
• Occupancy target: Management targets 70–72% occupancy next year, with a 200 bps EBITDA margin expansion to 26.5% as occupancy moves toward 72%. This target excludes the drag from new hospital expansions, for which anticipated EBITDA losses will be provided offline.
• ALOS decline stabilizing: Average length of stay declined due to day-care surgeries using robotics, making the system more efficient. Management does not expect further reduction.
• Karnataka bed reconfiguration: Operating beds reduced in Karnataka due to refurbishment in Mysore, replacing general wards with semi-private and private beds to align with insurance penetration trends.

Suneeta Reddy: "The guaranteed doctors are something where had planned last year and I think we've created a pipeline of new talent for our hospitals. So, you should not expect to see an increase in that. But what you will see is that these doctors when they start having started working, their payoff will be very good and therefore over a period of time margin improvement."

Pharmacy Business

• Dual-engine growth: Omnichannel front-end grew 21% while offline pharmacy distribution grew 17%, reported separately in the investor presentation. The business is on track for ₹10,000 crore revenue this year with 6% EBITDA.
• Margin recovery accelerating: Pharmacy EBITDA margin improved sequentially from 9.7% in Q4 to 12.2% in Q2, driven by operating cost reduction through automation and discretionary expense cuts. Higher costs in the online business from last year have started to come off.
• Near-term target: Management expects another 3–4% margin improvement in the next six months, with a trajectory toward near 20% EBITDA margin prior to operating costs.
• Store expansion pace: The plan to add 500-plus stores is on track, though H1 additions were slower than the prior year. Management did not explain the specific reason for the slower pace when asked.

Sanjeev Gupta: "another 3% to 4% is what I believe that should go up in another six months and going forward it should be near 20% is what we look at it."

Apollo 24/7 & Digital

• User base and GMV trajectory: The platform added 0.2 crore users this quarter, reaching 2.9 crore total. GMV is in line to deliver ₹3,000 crore this fiscal, with a target of ₹4,500–5,000 crore next year. Revenue-to-GMV conversion is targeted at ~40% next year.
• Breakeven on schedule: The business remains on track to achieve operational breakeven in Q4 FY24. Quarterly opex run rate is expected to fall to ₹150 crore or slightly lower in Q3 and Q4, with further reductions possible next fiscal year depending on technology investments.
• New verticals launching: Digital therapeutics and insurance verticals are starting this quarter, expanding the platform's scope beyond pharmacy and consultations.

Sanjeev Gupta: "I strongly believe that another Rs. 10 to Rs. 15 crore will further come down as we move forward. So, I'm looking at anything as a run rate of Rs. 150 crore or slightly lesser than that in Q3, Q4."

Expansion Pipeline

• Three new hospitals announced: A 250-bed hospital in Pune (expandable to 425 beds) at a cost of ₹675 crore, commissioning in Q1 FY25; a 225-bed hospital in Kolkata (expandable to 325 beds), commissioning by Q4 FY25; and a managed asset-light model in Rourkela with Steel Authority of India, commissioning in the coming quarter.
• Pune and Kolkata are constructed assets: Both are already built. Pune is close to receiving an occupation certificate; Kolkata was bought in an asset sale from a trust. This reduces construction risk and accelerates commissioning timelines.
• Rourkela asset-light model: No capital investment by Apollo; profit share arrangement with SAIL retaining one-third of profits and Apollo receiving the balance. Management noted such models are rare and attributed the win to Apollo's clinical reputation.
• Ongoing brownfield expansion: The 2,300-bed addition across eight locations at a cost of ₹3,400 crore over three financial years remains on track. Delhi expansion is proceeding after a court stay was vacated in Gurgaon; the asset is already bought and secured.
• Indraprastha Medical expansion: A neurosurgery center is being established with capacity addition of approximately 75 beds plus multi-level parking, with a two-year completion timeline.
• Funding and breakeven: All capex will be funded from internal accruals, with possible small debt only in the third year. New hospitals are expected to reach EBITDA breakeven in 12–18 months.

A. Krishnan: "It's not easy to get such kind of models. But I think given our reputation and our clinical prowess, I guess the Steel Authority wanted us to operate that asset and which is how we've got that."

AHLL & Other Businesses

• AHLL margins subdued: EBITDA at ₹32 crore versus ₹38 crore in Q2 FY23, impacted by ongoing network expansion and relocation of two Spectra units. Margin profile is expected to improve as the new network ramps up, though no specific timeline was given.
• International patient outlook: Management expects major traction from the Gurgaon facility once operational, with results from new international markets expected in the next 1–2 years.
• HealthCo fundraise: The company is looking for the right valuation and will not dilute below 10%. The fundraise could happen in the next 6–12 months, but management stated there is no pressure unless the right valuation is achieved.

Suneeta Reddy: "we will look at an investment where we believe the valuation is appropriate because we're quite sure we don't want to go below our dilution of 10%... there is no pressure unless we get the right valuation."

Guidance & Commitments

Key Metrics